Quantcast

Latest National Institute of Neurological Disorders and Stroke Stories

2008-10-16 12:00:25

NeoPharm, a biopharmaceutical company, has signed a cooperative R&D agreement with the National Institute of Neurological Diseases and Stroke, a part of the National Institutes of Health for research on a therapeutic agent for untreatable brain diseases in humans. Under the terms of the cooperative R&D agreement, National Institute of Neurological Diseases and Stroke (NINDS) will deliver NeoPharm's proprietary drug, Cintredekin Besudotox (IL13-PE38QQR) (IL-13), in conjunction with a...

2008-10-15 12:00:34

BOULDER, Colo., Oct. 15 /PRNewswire/ -- Bolder BioTechnology, Inc. announced today that it has been awarded a $1.6 million Phase II Continuing Renewal Small Business Innovation Research (SBIR) grant, entitled "Long-Acting Beta Interferon for Multiple Sclerosis", from the National Institute of Neurological Disorders and Stroke (NINDS) of The National Institutes of Health (NIH). Receipt of the entire grant award is contingent upon the achievement of certain research milestones. George (Joe)...

2008-10-15 09:00:47

NeoPharm, Inc. (NASDAQ: NEOL), today announced that the Company has signed a Cooperative Research and Development Agreement (the "CRADA") with the National Institute of Neurological Diseases and Stroke (NINDS), a part of the National Institutes of Health (NIH) for research on a therapeutic agent for untreatable brain diseases in humans. Under the terms of the CRADA, NINDS will deliver NeoPharm's proprietary drug, Cintredekin Besudotox (IL13-PE38QQR) ("IL-13"), in conjunction with a...

2008-08-20 09:01:30

Lixte Biotechnology Holdings has announced that the National Institute of Neurological Disorders and Stroke, National Institutes of Health and Lixte have filed a joint patent application for a new cancer biomarker. The new biomarker, present in many common cancers, is a target of drugs being evaluated by Lixte and the National Institute of Neurological Disorders and Stroke (NINDS) for the treatment of brain tumors. John Kovach, president and CEO of Lixte, said: "Studies with the research...

2008-08-19 09:01:12

EAST SETAUKET, N.Y., Aug. 19 /PRNewswire-FirstCall/ -- Lixte Biotechnology Holdings, Inc. (BULLETIN BOARD: LIXT) announced today that the National Institute of Neurological Disorders and Stroke (NINDS), National Institutes of Health (NIH) and Lixte filed a joint patent application identifying a biomarker, present in many common cancers, that is a target of drugs being evaluated by Lixte and NINDS for the treatment of brain tumors. Dr. John S. Kovach, President and CEO of Lixte, said,...

2008-07-03 09:01:19

A new study about National Institutes of Health research grants ranks Utah eighth among states for new business activity for every $1 million in NIH funding. The report from Families USA shows that Utah generated $2.3 million, above the national average of $2.21 million. The report said that in fiscal 2007, Utah received $153 million in funding, which led to the creation of 3,003 new jobs, $130 million in total wages and an average wage of $43,271 from those new jobs. Nationally, nearly...

2008-06-26 12:03:21

The National Institute of Neurological Disorders and Stroke, National Institutes of Health, and Lixte Biotechnology Holdings have extended co-operative research and development agreement to develop drugs for the treatment of brain cancers. The co-operative research and development agreement, initiated in March 2006, was extended through September 2009. John Kovach, president and CEO of Lixte, said: "The scientific interaction with the research team at the molecular pathogenesis unit,...

2008-06-25 12:00:00

EAST SETAUKET, N.Y., June 25 /PRNewswire-FirstCall/ -- Lixte Biotechnology Holdings (BULLETIN BOARD: LIXT) announced today that the National Institute of Neurological Disorders and Stroke (NINDS), National Institutes of Health (NIH) and Lixte Biotechnology Holdings, Inc. extended their Cooperative Research and Development Agreement (CRADA) to develop drugs for the treatment of brain cancers. The CRADA, initiated in March 2006 was extended through September 2009. Dr. John S. Kovach,...

2005-11-28 17:15:31

Most people with a rare type of dementia called primary progressive aphasia (PPA) have a specific combination of prion gene variants, a new study shows. The study is the first to link the prion protein gene to this disorder. It was funded in part by the National Institute of Neurological Disorders and Stroke (NINDS), part of the National Institutes of Health (NIH), and appears in the December 2005 issue of the Annals of Neurology.[1] The researchers, led by James A. Mastrianni, M.D., Ph.D.,...

1c77f060cb18e71b9b41ee350810236c1
2005-05-21 10:44:15

Unlike younger patients, there's little need to increase dose HealthDay News -- Daily aches and discomfort may become more common with age, but elderly Americans shouldn't have to increase their dosage of narcotic pain relievers to keep up with the pain, researchers report. On the other hand, people under 50 years of age may need to ramp up their dosage of these opioid pain-relieving medicines -- drugs like morphine, OxyContin and Percocet -- to achieve ongoing relief, reports a study in the...


Word of the Day
penuche
  • A fudgelike confection of brown sugar, cream or milk, and chopped nuts.
'Penuche' is a variant of 'panocha,' a coarse grade of sugar made in Mexico. 'Panocha' probably comes from the Spanish 'panoja, panocha,' ear of grain.
Related